Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.

Jennifer G. Whisenant,J. Oliver McIntyre,Todd E. Peterson,Hakmook Kang,Violeta Sanchez,H. Charles Manning,Carlos L. Arteaga,Thomas E. Yankeelov

Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.

2015

Jennifer G. Whisenant
J. Oliver McIntyre
Todd E. Peterson
Hakmook Kang
Violeta Sanchez
H. Charles Manning
Carlos L. Arteaga
Thomas E. Yankeelov

Purpose The objective of this study was to evaluate 3’-deoxy-3’-[18 F]fluorothymidine ([18 F]FLT) positron emission tomography (PET) as an early marker of trastuzumab response in HER2-overexpressing xenografts.

Keywords:

Neoplasm Transplantation
Breast cancer
Medicine
Nuclear medicine
Positron emission tomography
Trastuzumab
Immunohistochemistry
Cancer
human breast
treatment response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations